Invasive Fungal Infections Clinical Trial
— Ve-RIFIOfficial title:
Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-Comparative Study
Verified date | August 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Slovakia: State Institute for Drug Control |
Study type | Observational |
Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections. The study is conducted in Slovakia only.
Status | Completed |
Enrollment | 177 |
Est. completion date | November 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years and older |
Eligibility |
Inclusion Criteria: - Male or female patient of age 2 years or older. - High-risk patients with proven, probable or possible invasive fungal infection (IFI) according to the EORTC/MSG criteria. - Patients indicated for secondary prophylaxis of invasive aspergillosis. Exclusion Criteria: - Patients with known hypersensitivity to voriconazole or to any of the excipients. - Patients with contraindicated concomitant medications according to the SmPC. - Children less than 2 years of age. - Pregnancy and lactation. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Clinical and/or Mycological Efficacy by Response at the End of Treatment (EOT) Visit | Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, and no mycological culture performed. Participants could have had more than one response. Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines. | up to 2 weeks (EOT visit) | No |
Primary | Number of Participants With Clinical and/or Mycological Efficacy by Response at the Test-of-Cure Visit | Clinical, mycological responses: clinical cure, clinical improvement, no clinical cure, mycological cure, no mycological cure, no mycological culture performed, death, and lost from follow-up. Participants could have had more than one response. Responses were based on the investigator's judgement according to the Infectious Disease Society of America, European Conference on Infections in Leukemia, and European Committee on Antimicrobial Susceptibility Testing guidelines. | more than 2 weeks (Test-of-Cure visit) | No |
Primary | Number of Participants With Investigator's Satisfaction With the Efficacy of Voriconazole Assessment at the EOT Visit | Investigator's Satisfaction Responses: very good, good, moderate, poor. Responses were based on the investigator's judgement. | up to 2 weeks (EOT visit) | No |
Primary | Number of Participants With Investigator's Satisfaction With the Tolerability of Voriconazole Assessment at the EOT Visit | Investigator's Satisfaction Responses: very good, good, moderate, poor. Responses were based on the investigator's judgement. | up to 2 weeks (EOT visit) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05749380 -
Pharmacokinetics and Safety of AmBisome and DKF-5122
|
Phase 1 | |
Not yet recruiting |
NCT02527928 -
Cost-Effectiveness of Amphotericin B
|
N/A | |
Completed |
NCT02851680 -
Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.
|
N/A | |
Completed |
NCT03572049 -
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
|
Phase 2/Phase 3 | |
Suspended |
NCT05534529 -
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
|
Phase 1 | |
Completed |
NCT04024995 -
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
|
||
Completed |
NCT00745992 -
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients
|
||
Completed |
NCT06413056 -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
|
Phase 4 | |
Recruiting |
NCT05130723 -
Pharmacokinetics of Fluconazole in Children (2-18 Years)
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
Completed |
NCT03262584 -
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
|
||
Completed |
NCT02678598 -
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
|
N/A | |
Completed |
NCT05491733 -
A Bioequivalence Study of APX001 High-load and Low-load Tablets
|
Phase 1 | |
Not yet recruiting |
NCT06220370 -
PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.
|
||
Completed |
NCT04777058 -
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
|
||
Recruiting |
NCT03583164 -
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
|
Phase 2 | |
Completed |
NCT03174457 -
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
|
||
Completed |
NCT00750737 -
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
|
Phase 3 | |
Not yet recruiting |
NCT06346951 -
Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS)
|